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Abstract: Chemo- or radioresistance markedly impairs the efficacy of cancer therapy and involves anti-apoptotic 
signal transduction pathways that prevent cell death. In resistant cancer cells, both inhibitors of apoptosis 
proteins (IAPs) and nuclear factor-kappa B (NF-B) play a pivotal role in preventing apoptosis triggered by a variety 
of stresses, facilitating them as potential targets in cancer treatment. Furthermore, mounting evidences have 
established the crosstalks between IAPs (eg. XIAP, cIAP-1, cIAP-2) and proteins involved in NF-B signaling (eg. 
TRAF2, RIP1, TAB1). Second mitochondria-derived activator of caspases (Smac) is a mitochondrial protein that 
released into cytoplasm upon apoptotic stimuli. As Smac functions as an endogenous IAP inhibitor, small 
molecule Smac-mimetics are believed to neutralize IAPs function that results in liberating caspase activity and 
promoting apoptosis.  Moreover, recent studies show that Smac-mimetics may kill cancer cells in a different 
manner, which involves inducing ubiquitination of cIAPs, regulating NF-B signaling and facilitating TNF-
triggered, caspase-8-mediated apoptosis in a certain cancer cell types.  In other cancer cells that are resistant to 
TNF or chemo/radiotherapy, Smac-mimetic IAP-inhibitors can enhance ionizing radiation or tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, indicating the potential role of Smac-mimetics 
in overcoming acquired therapy-resistance. Such findings provide important impetus for utilizing IAP-inhibitors as 
novel adjuvant therapy for the TNFα–resistant, NF-κB constitutively active cancers that account for the majority of 
patients who are refractory to current therapeutic approaches. 
 




The aggressive cancer cell phenotype is the 
result of a variety of genetic and epigenetic 
alterations leading to deregulation of 
intracellular signaling pathways, including an 
impaired ability of the cancer cell to undergo 
apoptosis [1, 2]. Most of the current 
anticancer therapies work, at least in part, 
through inducing apoptosis in cancer cells [3-
6].  Lack of appropriate apoptosis due to 
defects in the normal apoptosis machinery 
plays a crucial role in the resistance of cancer 
cells to a wide variety of current anticancer 
therapies [7, 8].   Chemo- or radioresistance 
markedly impairs the efficacy of cancer 
therapy and involves anti-apoptotic signal 
transduction pathways that prevent cell death 
[9-11]. For example, primary or acquired 
resistance of hormone-refractory prostate 
cancer to current treatment protocols has 
been associated with apoptosis-resistance of 
cancer cells and is linked to the failure of 
therapies [12-14].   
 
Current and future efforts toward designing 
new therapies to improve survival and quality 
of life of cancer patients must include 
strategies that specifically target cancer cell 
resistance to current chemo/radiotherapies 
[13, 15]. In this review article, we will 
summarize the state of our knowledge for the 
role of both IAPs and NF-B in relation to 
cancer therapeutics resistance. Furthermore, 
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we will discuss the potential role of small 
molecule candidates that target apoptosis 
and/or NF-B signaling pathway on the 
sensitization of conventional cancer therapy.   
 
The inhibitor of apoptosis proteins are potent 
negative regulators of apoptosis and related to 
apoptosis-resistance 
 
Cancer cells will acquire resistance to 
apoptosis by upregulating multiple pro-survival 
factors. The inhibitors of apoptosis proteins 
(IAPs) are a pivotal class of intrinsic cellular 
inhibitors of apoptosis [16-19].  IAPs widely 
and potently suppress apoptosis against a 
large variety of apoptotic stimuli, including 
chemotherapeutic agents, radiation and 
immunotherapy in cancer cells [20, 21]. In 
human, eight IAPs were identified so far (Table 
1), all can block caspase cascade, but only 
some of them directly interact with caspases 
[22]. IAPs are characterized by the presence of 
one to three domains known as baculoviral IAP 
repeat (BIR) domains and belong to a larger 
family of proteins, called the BIR-domain-
containing proteins (BIRPs) [16].  
 
Since the IAPs function at the convergence of 
both mitochondria pathway and death 
receptor pathway, they are described as an 
apoptosis “brake” and IAP antagonists 
function to release the “brake” [14, 23]. Most 
components of the major cell death regulatory 
pathways have been implicated in radiation-
induced cell death [24]. Some of these 
apoptosis pathway proteins have overlapping 
functions and compensatory pathways, and 
these apoptosis pathways have extensive 
cross-talks [24].  Inside a live cell upon 
irradiation, multiple apoptosis pathway 
proteins are involved in the shifting of the 
balance of life and death signals. In the 
context of IAP-inhibitor treatment and most 
conventional therapy, the relative levels of 
individual apoptosis pathway proteins and 
their roles in the process of irradiation-induced 
cell death dictate the outcome of the cell’s 
response to therapy. Therefore, investigation 
of the potential role of apoptosis pathway 
proteins in IAP-inhibitor-mediated sensitization 
will provide critical information as to how the 
IAP-inhibitors work in the context of radiation, 
and what types of cells may respond better to 
the therapy. The latter has clear clinical 
relevance in that the information will be useful 
to predict or select the patients who will 
benefit the most from the molecular therapy 
targeting IAPs [14, 23]. 
 
Although these BIRP proteins were all initially 
called IAP proteins, it is apparent that they are 
divided into two distinct groups based upon 
their binding properties to caspases and 
inhibition of caspase activity. The first group of 
mammalian BIRPs includes XIAP (BIRC4), cIAP-
1 (BIRC2), cIAP-2 (BIRC3), ML-IAP (BIRC7), 
NAIP (BIRC1) and ILP2 (BIRC8) (Table 1).  
These IAP proteins potently bind to and inhibit 
caspase-3, -7 and -9 and function as potent 
apoptosis inhibitors (Figure 1). The second 
group of BIRPs includes the mammalian 
proteins Survivin (BIRC5) and Bruce (BIRC6) as 
well as BIR-containing proteins in yeasts and 
C. elegans [16] (Table 1). In contrast to the 
first group of BIRPs, these Survivin-like BIRPs 
don’t bind to caspases.  In addition to their 
potent anti-apoptotic activity, these Survivin-
like BIRPs also regulate cytokinesis and 
mitotic spindle formation [25, 26].   
 
X-linked IAP protein (XIAP) is the first well-
characterized IAP family member due to its 
potent anti-apoptosis activity [17, 19, 27]. 
XIAP protein was found to be expressed in 
most of the NCI 60 human cancer cell lines 
[28]. Analysis of tumor samples in 78 
previously untreated patients showed that 
those with lower levels of XIAP had significantly 
longer survival [28].   Two regions in XIAP 
confer different specificity in the inhibition of 
caspase-3, -7, and -9. The third BIR domain 
(BIR3) of XIAP selectively targets caspase-9, 
whereas the linker region between BIR1 and 
BIR2 of XIAP inhibits both caspase-3 and 
caspase-7, the effector caspases that triggers 
downstream apoptosis [23, 29] (Figure 1).  
Table 1. The inhibitor of apoptosis proteins 
family  
Gene Protein 
BIRC 1 NAIP 
BIRC 2 cIAP-1 
BIRC 3 cIAP-2 
BIRC 4 XIAP (ILP1) 
BIRC 5 Survivin 
BIRC 6 Bruce (Apollon) 
BIRC 7 ML-IAP (livin, K-IAP) 
BIRC 8 ILP2 (TsIAP) 
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While XIAP prevents the activation of all three 
caspases, it was shown that the interaction of 
XIAP with caspase-9 is the most critical for its 
inhibition of apoptosis [16].  
In contrast to XIAP, cIAP-1 and cIAP-2 are weak 
caspase inhibitors in vitro [30]. Although the 
role of cIAP-1 and -2 in apoptosis is less 
defined, their function on the cellular 
Figure 1: Apoptosis pathways in mammalian cells. Apoptosis activation by the extrinsic pathway involves the 
binding of extracellular death ligands (such as TNF ligand/TRAIL) to death receptors, provoking the 
recruitment of adaptor proteins, such as the Fas-associated death domain protein (FADD) and recruiting 
caspase-8. Active caspase-8 then activates effector caspase-3 and/or -7. In some situations, extrinsic death 
signals can crosstalk with the intrinsic pathway through caspase-8-mediated proteolysis of BID (BH3-
interacting domain death agonist). Truncated BID (tBID) can promote mitochondrial cytochrome c release and 
assembly of the apoptosome. In the intrinsic pathway, stresses such as radiation or chemotherapeutic agents 
target mitochondria and induce efflux of intermembrane space proteins, such as cytochrome c and 
Smac/DIABLO, into the cytosol, by the formation of BAK–BAX oligomers on mitochondrial outer membranes. 
On release from mitochondria, cytochrome c can join the apoptosome assembly. Active caspase-9 then 
propagates a cascade of further caspase activation events. The inhibitors of apoptosis proteins (IAPs) is an 
important class of intrinsic cellular apoptosis inhibitors that function as potent endogenous apoptosis 
inhibitors by directly binding to and effectively inhibiting both initiator caspase-9 and effector caspases -3/-7. 
Smac can neutralize IAP inhibition of caspases thus functions as an endogenous IAP-antagonist. Functional 
blockade of IAPs by Smac results in facilitating caspase activation and apoptosis. 
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responses other than apoptosis are widely 
reported. Over ten years before, several 
studies have proposed that both cIAP-1 and 
cIAP-2 were associated with the TNF receptor 
1 signaling complex [31-33].  Moreover, the 
cIAP-1 and -2 do not directly contact TNF-
receptor 2, but rather physiologically interact 
with TNF-receptor associated factors (TRAFs) 
[32], and regulate their function by mutually 
ubiquitination [34, 35].  Through binding to 
TRAF2, cIAPs are recruited to TNFR signaling 
complexes where they regulate the activation 
of caspase-8 [32, 36]. Also, cIAP-1 and cIAP-2 
directly ubiquitinate RIP1 and induce 
constitutive RIP1 ubiquitination in cancer cells 
and demonstrate that constitutively 
ubiquitinated RIP1 associates with the 
prosurvival kinase TAK1 [37]. Collectively, 
these studies elucidate the potential role of 
cIAPs on regulating TNF-induced both 
apoptosis and NF-B signaling.  
 
Second mitochondria-derived activator of 
Caspases (Smac) was identified as a pro-
apoptotic factor released from mitochondria 
into the cytosol triggered by multiple apoptosis 
stimuli [38-41]. Upon stimulation, the released 
Smac physically interacts with XIAP through 
the N-terminal four conserved amino acid 
residues (AVPI) that bind to the baculoviral IAP 
repeat 3 (BIR3) domain of XIAP, and eliminate 
the inhibitory effect of XIAP on caspase 
activation [42-44]. Therefore, Smac functions 
as an endogenous IAP-antagonist. Due to the 
potent pro-apoptotic role of Smac, synthetic 
small molecule Smac-mimicking compounds 
(Smac-mimetics) are being developed to 
sensitize apoptosis-resistant cancer cells to 
various apoptotic stimuli [45, 46]. Smac-
mimetic IAP-antagonists induce TNF-
dependent apoptosis in several transformed 
cell lines [47-49]. Other reports show that 
small molecule Smac-mimetics successfully 
sensitize TRAIL-induced apoptosis by blocking 
functions of IAPs in multiple cancer cells [38, 
50-52]. Also, Smac-mimetic tetrapeptide 
pSmac-8c significantly sensitized androgen-
independent prostate cancer cells to 
chemotherapeutic agents [53, 54].  These 
studies manifest that mimicking Smac may 
represent a promising strategy for restoring 
defective apoptosis signaling in human cancer 
therapy. Furthermore, it has recently been 
reported that Smac can potentiate apoptosis 
by simultaneously antagonizing caspase-IAP 
interactions and repressing IAP ubiquitin ligase 
activities [55]. Yoon, et al [56] identified a 
Smac-binding protein, NADE.  The interaction 
between Smac and NADE regulates apoptosis 
through the inhibition of Smac ubiquitination 
[56]. Dr. Duckett’s group reported that some 
cytoprotective IAPs can inhibit apoptosis 
through the neutralization of IAP antagonists, 
such as Smac, rather than by directly inhibiting 
caspases [27].  These recent studies suggest 
that endogenous Smac protein plays more 
complicated roles than expected in apoptosis.   
In a subset of highly sensitive tumor cell lines, 
activity of Smac mimetic compounds is 
dependent on TNF signaling. Mechanistic 
studies indicate that in the system they tested, 
XIAP is a positive modulator of TNF induction 
whereas cIAP-1 negatively regulates TNF-
mediated apoptosis, indicating the opposite 
effect of XIAP versus cIAP-1 on modulation 
TNF signaling [57]. Also, Smac-mimic IAP-
antagonists sensitize TRAIL-induced apoptosis 
by blocking XIAP function in multiple tumor 
models, including breast cancer [50], multiple 
myeloma [52], glioblastoma [38], and ovarian 
cancer [51]. 
 
Inhibitor of apoptosis proteins are attractive 
molecular targets for designing novel therapy 
for human cancers 
 
XIAP  is so far the most potent inhibitor of 
apoptosis among all the IAP proteins [17]. XIAP 
effectively inhibits both intrinsic and extrinsic 
apoptosis pathways by binding and inhibiting 
the initiator caspase-9 and effector caspases 
(caspase-3 and -7), whose activity is crucial for 
the execution of apoptosis [17, 58]. Because 
effector caspase activity is both necessary and 
sufficient for irrevocable programmed cell 
death, XIAP functions as a gatekeeper to this 
final stage of the process [38].  XIAP is 
overexpressed in many cancer cell lines and 
tumor tissues but not in normal cells, and a 
high level of XIAP results in apoptosis-
resistance of cancer cells to a wide variety of 
therapeutic agents [59].  The multiple 
biological activities of XIAP, its unique 
translational and post-translational control and 
the centrality of the caspase cascade make 
XIAP an exceptionally promising molecular 
target for modulating apoptosis [14, 19, 60]. 
For example, overexpression of XIAP increases 
resistance to tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL)-induced 
apoptosis, while downregulation of XIAP 
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restores cell response to TRAIL [61-63]. 
 
Since IAPs block apoptosis at the down-stream 
effector phase, a point where multiple 
apoptosis signaling pathways converge, 
strategies targeting IAP may prove to be highly 
effective for overcoming apoptosis-resistance 
in human cancers that overexpress IAPs. The 
link between therapy resistance and IAPs is 
supported by recent studies in which the 
suppression of XIAP levels by RNA interference 
or antisense indeed sensitized XIAP-
overexpressing cancer cells to death receptor-
induced apoptosis as well as radiation [64, 
65]. Combination of irradiation and inhibition 
of XIAP through the antisense approach 
resulted in improved tumor control by 
radiotherapy in vivo [66], advocating a distinct 
role for XIAP in radiation resistant phenotype 
of human cancers, and providing a proof-of-
concept that IAPs may be a novel and 
promising target for chemo/ radiosensitization 
of human cancers. Loss of XIAP by RNAi also 
sensitized cancer cells to a certain 
chemotherapeutic agents and TRAIL, and the 
increased sensitivity of the XIAP shRNA cells 
was correlated with enhanced Caspase 
activation [67]. We have found that embelin, 
the first non-peptidic natural XIAP inhibitor 
identified by us, induces apoptosis in prostate 
cancer cells [68].  Embelin sensitized TRAIL-
induced apoptosis in pancreatic cancer cells 
[69]. These findings provide a strong rationale 
that downmodulation of overexpressed XIAP 
will achieve sensitization on current 
therapeutic modality.  
 
Through computational structure-based 3D-
database search and rational design, a series 
of small molecule inhibitors of IAPs have been 
discovered and synthesized, which show 
potent therapeutic activity to overcome 
apoptosis-resistance in vitro in cancer cells 
overexpressing IAPs while minimize side-effect 
on normal cells with relative low level of IAPs 
[38, 51]. Based on the high-resolution 
experimental 3D structure of Smac in complex 
with the XIAP BIR3 domain, Wang and his 
colleagues have designed and synthesized a 
group of potent non-peptidic compounds that 
mimic the tetra-peptide at the N-terminal of 
natural Smac [53, 54]. These cell-permeable 
compounds show at least 20-fold more 
potential than the natural Smac peptide in 
binding to the XIAP BIR3 domain in a cell-free 
system [53, 54, 70]. It has been shown that 
SH130, one of the most potential compounds, 
enhances ionizing radiation-induced apoptosis 
in vitro and combination therapy achieves 
significant tumor regression in hormone-
refractory prostate cancer models [71]. Also, 
SH122, another potential compound, 
promotes TRAIL-mediated cell death in several 
human prostate cancer cell lines (Dai et al., 
manuscript submitted). These findings suggest 
that Smac-mimetic IAP-antagonist can 
sensitize cell-killing effect by either radiation or 
death-receptor therapy.  
 
However, little is known about the role of 
endogenous Smac in cells treated with Smac-
mimetic IAP-inhibitors and irradiation. In 
multiple human cancer models, full-length 
Smac enhanced gamma-irradiation-induced 
apoptosis by loss of mitochondrial membrane 
potential, cytochrome c release, and activation 
of a serial of caspases [72]. Takasawa et al. 
shows that the sustained release of 
Smac/DIABLO from mitochondria is an 
important event for the onset of apoptosis in 
keratinocytes exposed to UVB irradiation [40]. 
In hormone refractory prostate cancer, small 
molecule IAP inhibitors exhibit a promising 
therapeutic potential to overcome resistance 
of prostate cancer cells to radiation-induced 
growth inhibition, both in vitro and in vivo in 
xenograft tumor models, suggesting that 
targeting IAPs may be a promising approach 
for radiosensitization of human prostate 
cancer with high levels of IAPs [71], and 
provides important impetus for utilizing IAP-
inhibitors as an adjuvant therapy for the 
TNFα–resistant cancers that account for the 
majority of patients who are refractory to 
radiation/chemotherapy. 
 
NF-B is a pro-survival factor that blocks 
apoptosis and promote therapeutic resistance 
 
The transcription factor NF-B pathway plays 
important roles in the control of cell 
proliferation, apoptosis, inflammation, cell 
signaling transduction, and other physiological 
processes  [73, 74].  Because the  disorder  of 
these physiological processes has been linked 
with the onset of cancers, NF-B has been 
described as a major culprit in cancer [74]. 
Current evidences have also shown that NF-B 
participates in the processes of angiogenesis, 
invasion, and metastasis [73, 75, 76].  
Moreover, NF-B is critically involved in the 
processes of development and progression of 
cancers, raising its importance in cancer 
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Figure 2: Crosstalk between ionizing radiation-induced apoptosis and NF-κB pathway. IR activates both 
apoptosis and NF-κB signaling pathway. IR triggers instrinsic apoptosis pathway as described in Figure 1. 
Simultaneously, NF-κB pathway is activated by IR-induced DNA damage. IR induced double-strand breaks 
(DSB) directly activates initiator kinase ATM and PIDD, which further recruit NEMO, also known as IKKγ, by 
multiple steps of posttranslational modification. Modified NEMO joins formation of IKKs signalosome and 
further activates classical NF-κB pathway. Upon apoptotic stimuli (IR or TNFα), natural Smac can bind to 
both XIAP and cIAPs, and predominantly neutralize the suppression effect of XIAP on caspases. It has been 
shown that cIAP-1 physically binds to TRAF2 and regulates its function through ubiquitination in TNFα 
signaling. Smac-mimetics that function as IAP-antagonists, not only promote caspase activation by 
neutralizing IAPs, but also interferes the stability and interaction between cIAP-1/2 and TRAF2, thus 
modulate the balance between apoptosis and NF-κB signaling pathway. 
research [77]. NF-B is constitutively activated 
in most of human cancers, suggesting that the 
activation of NF-B is involved in the process 
of carcinogenesis. Therefore, targeting NF-B 
is attracting more attention as a novel 
preventive and therapeutic strategy against 
human cancers.  
 
Besides death receptors, genotoxic stress also 
activates NF-B signaling pathway that 
attenuates apoptotic responses. Blocking NF-
B pathway can sensitize cancer cells to 
chemotherapeutic agents and radiation [78-
82]. It has been shown that NF-B is activated 
by ionizing radiation (IR)-induced double-
strand breaks (DSB) [81-84] (Figure 2). IR-
induced DSB directly activates ATM and PIDD 
(p53-inducible death domain –containing 
protein), which further recruit NEMO, a 
member of IKKs signalsome, by serial of 
posttranslational modification [85, 86]. 
Modified NEMO participates to the formation 
of IKK complex, and thus activates 
downstream NF-B pathway through 
degradation of IB and liberate NF-B 
heterodimer from cytosol into nucleus [87, 
88]. On the other side, IR can directly trigger 
intrinsic apoptosis pathway through activation 
of pro-apoptotic Bcl-2 family members Bax and 
Bak [89, 90], and activates downstream 
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caspase cascade and apoptosis (Figure 2). 
 
It has been established that NF-κB is the major 
survival factor in preventing apoptosis, and 
inhibition of this transcription factor may 
improve the efficacy of apoptosis-inducing 
cancer therapies [74, 91, 92]. Due to its 
constitutive or treatment-induced activity, NF-
κB functions mainly as an inhibitor of 
apoptosis and is prerequisite for cell survival. 
NF-κB-mediated protection of lymphoid cells 
from antigen receptor- and death receptor-
induced apoptosis plays an instrumental role 
in activation of the immune response [93]. In 
addition, NF-κB may also protect cells from 
cellular stresses, such as DNA damage, which 
activate the mitochondrial-dependent 
“intrinsic” pathway [93-96].  Suppression of 
NF-κB by genetic or chemical inhibitors 
induces the apoptosis and/or restores the 
apoptotic response after treatment with 
chemotherapeutic agents or radiation in 
various tumor cells, thus overcoming NF-κB-
mediated chemo-/radioresistance [95, 97, 
98]. Moreover, the mechanisms of action of 
several more ancient drugs have been re-
evaluated and some of them were discovered 
to act at least partially through NF-κB 
inhibition. However, the role of NF-κB in the 
control of apoptosis is not unambiguous and 
this factor is also, in some experimental 
conditions, required for the induction of 
apoptosis either of mutated cells or in 
response to anti-cancer agents [98-101]. 
Therefore, a precise knowledge of the 
signaling pathways controlling NF-κB as well as 
of the NF-κB target genes is essential in order 
to define who will benefit the most from the 
anti-NF-κB therapies. More preclinical studies 
are needed to determine a tolerable and 
efficacious dose and schedule for NF-κB 
inhibitors [73, 102-104]. Other NF-κB 
inhibitors might also have a greater effect on 
sensitizing anticancer agents. It is important to 
clarify what type of NF-κB inhibitors is most 
effective and least toxic. 
 
Molecular targeting of NF-B pathway in 
sensitization of conventional therapies 
 
Many chemotherapeutic agents trigger the 
cell-death process through activation of the 
tumor-suppressor protein p53 [105]. However, 
NF-B is also activated in response to 
treatment that attenuates p53-medieated cell 
death [106] with chemotherapy and radiation 
therapy. The NF-B pathway thus impinges on 
many aspects of cell survival. Recent studies 
indicate that the effects of conventional 
cancer therapeutics could be enhanced by 
natural and synthetic NF-B inhibitors, 
suggesting that down-regulation of NF-B 
could sensitize cancer cells to conventional 
therapeutics [74, 103]. For example, 
genistein, one of three main isoflavones found 
in soybeans, inactivates NF-B and leads to 
increased growth inhibition and apoptosis 
induced by various chemotherapeutic agents 
and promote drug-induced cell-killing effect in 
many types of cancers [107, 108]. Indole-3-
carbinol that is produced from cruciferous 
vegetables, significantly inhibited NF-B DNA 
binding activity in prostate and breast cancer 
cells, corresponding with the inhibition of cell 
proliferation and the induction of apoptosis 
[109, 110].  
 
As it is well-established that in classical NF-B 
pathway, proteasomes are responsible for 
IB degradation, which facilitates NF-B 
nuclear translocation and activates multiple 
target gene expression [111], modulation of 
proteasomal function with specific inhibitors 
has been demonstrated as a promising 
strategy for the treatment of human cancers, 
presumably by suppression NF-B [112, 113]. 
In preclinical cancer models, proteasome 
inhibitors alone induce apoptosis [113-115], 
as well as overcome radioresistance of tumor 
cells and enhance radiation–mediated 
response, typically apoptosis [114]. 
Bortezomib (Velcade; PS-341), the first 
proteasome inhibitor to be used in clinical 
applications, has demonstrated impressive 
antitumor activity, both as a single agent and 
in combination with conventional therapies 
[116-118]. More significantly, in preclinical 
studies, bortezomib in combination with 
radiation therapy has been shown to achieve 
potential therapeutic benefits in various 
cancers [119, 120]. Besides bortezomib, 
many other proteasome inhibitory candidates 
are under investigation in preclinical models, 
either alone or in combination with 
conventional therapies [121, 122]. We have 
found that Celastrol, a natural proteasome 
inhibitor, enhances therapeutic efficacy of 
ionizing radiation both in vitro and in vivo, 
typically by increasing apoptosis and 
decreasing both primary and acquired NF-B 
activity (Dai et al., manuscript in revision). 
These studies provide substantial evidence 
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that proteasome inhibitors can potentiate 
response of cancer cells to chemotherapeutic 
agents or radiation. 
 
Crosstalks between apoptosis and NF-B 
signaling by IAP-antagonist   
 
As NF-B has been proved to play a pivotal 
role in mediating cell survival, blockade of NF-
B activation can shift the tumor 
survival/death balance towards apoptosis, 
suggesting that targeting IAPs and/or NF-B 
may become a potential approach to 
overcoming resistance of human cancer.  
 
The cytokine TNF elicits a wide range of 
biological responses, including inflammation, 
cell proliferation, differentiation, and 
apoptosis. Although the molecular 
mechanisms of TNF signaling have been 
largely elucidated, the principle that regulates 
the balance of life and death is still unknown. 
Several reviews have focused on the crosstalk 
that exists between proteins of the TNF 
receptor (TNF-R) which are involved in the 
initiation of NF-B activation or apoptosis 
[106, 123, 124]. At least three different 
mechanisms of regulation can be 
distinguished: (i) NF-B-mediated recruitment 
of TNF-R complex [125]; (ii) NF-B-
independent protection against apoptosis by 
the TRAF2-mediated recruitment of 
antiapoptotic proteins [126]; (iii) dual 
activation of apoptosis and NF-B by a single 
molecule, such as TNF, TRAIL and radiation 
Figure 3: Crosstalk between apoptosis and NF-κB signaling by IAP-antagonist. TNFα induces both apoptosis 
and NF-κB activation in cancer cells. TNFα induces extrinsic apoptosis via activation of caspase cascade that 
involves initiator Caspase-8 and effector Caspase-3. IAPs (XIAP, cIAP-1 and cIAP-2) are anti-apoptotic proteins 
that block caspase- mediated apoptosis. Paradoxically, TNFα still activates NF-κB and promotes cell survival 
that counteracts with apoptosis. The classical NF-κB pathway that is mediated by IKKs signalosome can be 
triggered either by TNFα via TRAF2 and RIP1, or alternatively, by TGFβ via TAB1 and TAK1. Multiple studies 
have established crosstalk between IAPs and proteins that mediate NF-κB signaling pathway (see text). Smac 
mimetics that function as IAP antagonists can modulate the interaction between IAP proteins and NF-κB 
signaling proteins, which leads to TNFα-triggered apoptosis primarily via an autocrine manner (see text). 
TNFα, tumor necrosis factor alpha; TGFβ, transforming growth factor beta; TRAF2, TNF receptor-associated 
factor 2; RIP1, receptor interacting protein 1; TAK1, TGFβ activated kinase 1; TAB1, TAK1 bind protein 1; IKK, 
IκBα kinase. 
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[74, 98]. Overall, the multiple facets of 
crosstalk have been established between the 
apoptosis and NF-B signaling pathways. A 
direct evidence is that cIAP-1 physically binds 
to TRAF2 through its BIR1 domain and 
regulates its biological function through 
ubiquitination [32, 127-130], suggesting a 
potential role of cIAP-1 on linking apoptosis 
and NF-B pathways (Figure 2). Interestingly, a 
recent study shows that TRAF2-knockdown by 
siRNA indeed radiosensitizes cancer cells via 
reduced NF-κB activation, suggesting that 
TRAF2 is an attractive drug target for 
anticancer therapy and radiosensitization 
[131]. Function as an adaptor protein in NF-B 
signaling, TRAF2 may thus play a potential role 
in protecting radiation-induced cell death, and 
establish the crosstalk between NF-B and 
DNA damage-induced apoptosis (Figure 2).   
 
Studies in recent two years tend to elucidate 
the potential mechanism in TNF signaling by 
Smac-mimetics in cancer cells. It has been 
demonstrated that Smac-mimetics stimulate 
autoubiquitination of cIAPs, resulting in their 
proteasomal degradation [30, 48] (Figure 3). 
This in turn leads to NIK stabilization and 
facilitates RIP1 recruitment [49, 132] (Figure 
3). Moreover, cIAP-1 and cIAP-2 promote 
cancer cell survival by functioning as E3 
ubiquitin ligases that maintain constitutive 
ubiquitination of the RIP1 adaptor protein, 
suggesting that constitutively ubiquitinated 
RIP1 associates with the prosurvival kinase 
TAK1 [37]. Collective reports demonstrate that 
either cIAP-1 or 2 is required for proper RIP1 
polyubiquitination and NF-B activation upon 
TNF treatment [37, 132] (Figure 3). This 
results in the activation of the noncanonical 
and canonical NF-κB pathways, causing 
autocrine TNFα production in a substantial 
number of tumor cells. Besides cIAPs, a recent 
study proposes that BIR1 domain of XIAP, 
which has no  previously ascribed function, 
directly interacts with TAB1 to induce NF-B 
activation [133] (Figure 3).  Smac, the 
antagonist for caspase inhibition by XIAP, also 
inhibits the XIAP/TAB1 interaction. Disruption 
of BIR1 dimerization abolishes XIAP-mediated 
NF-B activation, implicating a proximity-
induced mechanism for TAK1 activation [133]. 
Taken together, mounting experimental 
evidence indicate that IAPs function as 
“bridging” molecules that mediate cross-talk 
between the apoptosis pathway and NF-κB 
pathway. 
 As multiple recent studies suggest the role of 
IAPs on the crosstalks between apoptosis and 
NF-B pathway [37, 47-49, 57, 132-134] 
(Figure 3), it is reasonable to speculate that an 
IAP inhibitor may also function as a modulator 
in regulating such crosstalk. Indeed, several 
Smac-mimetic IAP-inhibitors can induce TNF-
dependent apoptosis in several transformed 
cell lines, via cIAP-1 down-regulation and NF-
κB activation [47-49]. Blocking NF-B 
activation reduced TNF production and 
protected cells from Smac-mimetics-induced 
cell death (Figure 2). Ahn et al. suggests that 
embelin sequentially inhibits NF-κB activation 
induced by TNFα at the IκBα kinase (IKK), IκBα 
degradation, and RelA nuclear translocation 
levels in several cancer cell lines [135]. Other 
studies show that Smac mimetics lead to 
sensitivity to TNFα-induced cell death, likely 
through the degradation of cIAPs and by 
favoring the formation of a RIP1-dependent 
caspase-8-activating complex [136]. 
Highlighting the potential of Smac mimetics for 
clinical application will validate that cancer 
cells that are sensitive to Smac-mimetic 
treatment in vitro are also responsive to the 
same treatment in an in vivo mouse model. 
AEG40730, a Smac mimetic dimer compound, 
binds to cIAP-1 and cIAP-2, facilitates their 
autoubiquitination and proteasomal 
degradation, and causes a dramatic reduction 
in RIP1 ubiquitination [37]. When 
deubiquitinated by AEG40730 treatment, RIP1 
binds caspase-8 and induces apoptosis in 
cancer cells [37]. In addition, in Smac-mimetic 
sensitive cell lines, apoptosis caused by Smac-
mimetics is blocked by the caspase-8 inhibitor 
crmA and that IAP antagonists activate NF-B 
signaling via inhibition of cIAP-1 [48]. In those 
transformed tumor lines, IAP antagonist 
induced NF-B-stimulated production of TNF 
that killed cells in an autocrine fashion. 
Inhibition of NF-B reduced TNF production, 
and blocking NF-B activation or TNF allowed 
tumor cells to survive Smac-mimetic-induced 
apoptosis [48]. Moreover, in a subset of highly 
sensitive tumor cell lines, XIAP is a positive 
modulator of TNF production whereas cIAP-1 
negatively regulates TNF-mediated apoptosis 
[57]. It is interesting that Smac mimetics 
induced degradation of cIAPs in certain types 
of cancer cell lines, suggesting that additional 
switch points control the sensitivity to Smac 
mimetics [30].  
 
 In a vast amount of solid tumors that are 
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resistant to therapeutics, for example, most of 
androgen-independent human prostate 
cancers exert highly constitutive NF-κB activity 
[75, 137] that may result in resistance to 
TNFα. How these majority resistant cancer 
cells respond to IAP-inhibitors remains to be 
investigated. In our recent publication [71], we 
found that those androgen-independent 
prostate cancer cells are highly resistant to 
Smac-mimetics, which has a IAP-binding 
affinity comparable to that of the compounds 
used in other reports [47-49]. Surprisingly, 
although Smac-mimetics alone hardly show 
any cell-killing effect both in vitro and in vivo, 
they potently sensitize those TNFα–resistant 
cells to radiation-induced growth inhibition and 
apoptosis, which might involve blocking 
radiation-induced NF-κB activation [71]. 
Moreover, such Smac-mimetic compound 
treatment does not induce cIAP-1 degradation, 
TNF upregulation and NF-κB activation when 
used alone in those resistant cells [71]. This 
mode of action of Smac-mimetic IAP-inhibitor 
is distinct from that in TNFα–sensitive cells 
reported recently [47-49] . Similarly, another 
study indicates that blockade of IAPs by a 
small molecule Smac-mimetic compound 
promotes TRAIL-induced apoptosis in TRAIL-
resistant prostate cancer cells, via modulating 
both the apoptosis pathway and NF-B 
pathway (Dai et al, manuscript submitted). 
This discrepancy of the mechanisms of Smac-
mimetic IAP-inhibitors in chemo/ 
radiosensitization has significant clinical 
implications and provides important impetus 
for utilizing IAP-inhibitors as an adjuvant 
therapy for the TNFα–resistant, NF-κB 
constitutively active cancers that account for 
the majority of patients who are refractory to 
current therapeutic approaches. 
 
Conclusion and perspective 
 
Conventional chemo/radiotherapies the most 
commonly used current therapies for cancer 
patients, however primary or acquired 
resistance remains to be a major challenge in 
clinic and is emerging as a significant 
impediment to effective cancer treatment. 
Although both IAPs and NF-B pathways have 
been subjected to intense preclinical and 
clinical studies, the detailed clinically relevant 
correlation between these two classes of 
proteins still remains unclear. Answers to such 
question will provide a clear rationale for 
combining Smac-mimetic IAP-antagonists with 
conventional therapy that will achieve a 
significantly improved therapeutic outcome. 
 
Mounting evidences have established the 
potential crosstalks between IAPs (eg. XIAP, 
cIAP-1, cIAP-2) and the proteins that are 
involved in NF-B signaling (eg. TRAF2, RIP1, 
TAB1). As Smac functions as an endogenous 
IAP inhibitor, small molecule Smac-mimetics 
are believed to neutralize IAPs function that 
promotes apoptosis. However, Smac-mimetics 
may kill cancer cells in a different manner, 
which involves inducing ubiquitination of 
cIAPs, regulating NF-B signaling and 
facilitating TNF-triggered, caspase-8-
mediated apoptosis in a certain cancer cell 
types. In other cancer cells that are resistant 
to TNF or chemo/radiotherapy, exhibit a 
promising therapeutic potential to overcome 
resistance of cancer cells to radiation therapy, 
at least in part, by suppressing NF-B 
activation. For example, in hormone-refractory 
prostate cancer, molecular modulation of IAPs 
and/or NF-B has been proven to be a novel 
adjuvant approach to enhance the efficacy of 
radiation therapy [14, 15, 71, 73, 75, 138]. 
Therefore, IAP antagonists may be developed 
as a personalized medicine in IAP-targeting 
molecular therapy and establish promising 
novel strategy to overcome the resistance to 
current therapies, with the ultimate goal of 
improving the survival of cancer patients who 
will benefit the most from the individualized 
therapy modality. This strategy may also 
benefit patients of other malignancies with 
high levels of IAPs and high constitutive NF-B 
activity in a clinical setting.  
 
In the clinic, continued treatment with potent 
IAP-inhibitors throughout the cycles of 
chemo/radiotherapy may help to further 
reduce or eliminate the “minimal residual 
disease”, thus may reduce the risk of tumor 
local recurrence as well as metastasis. A 
rationale patient screen based on individual 
genetic background will help to optimize the 
personalized therapeutic advantage. 
Therefore, the combination of IAP-targeting 
molecular therapy and conventional chemo/ 
radiotherapy may become a promising novel 
strategy to enhance the efficacy of current 
cancer treatments and ultimately improve the 
survival of cancer patients. 
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